PTTG2 CRISPR/Cas9 KO Plasmid (h): sc-418367
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PTTG2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the PTTG2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PTTG2 CRISPR/Cas9 KO Plasmid (h) | sc-418367 | 20 µg | $397.00 |
Overview
PTTG2 (pituitary tumor-transforming gene 2) encodes a securin-like protein implicated in regulation of sister chromatid separation and cell-cycle progression, with links to mitotic checkpoint control and maintenance of genomic stability. As part of pathways that coordinate anaphase onset and protease activity involved in chromosomal segregation, altered PTTG2 expression can influence proliferation, aneuploidy, and cellular stress responses. Dysregulation of PTTG family members has been reported across multiple tumor types, supporting investigation of PTTG2 in oncogenic signaling contexts and cell-cycle–driven phenotypes. Human PTTG2 is therefore relevant for mechanistic studies of mitosis, replication-associated damage, and transcriptional programs coupled to proliferative state.
PTTG2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the PTTG2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the PTTG2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the PTTG2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PTTG2 protein expression.
This CRISPR knockout system enables efficient generation of PTTG2-deficient cell models for investigation of PTTG2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting PTTG2 exon(s) critical for PTTG2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple PTTG2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by PTTG2 CRISPR/Cas9 KO Plasmid (h) and PTTG2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the PTTG2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by PTTG2 HDR Plasmid (h) and PTTG2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by PTTG2 homology arms to support homology-directed repair at defined PTTG2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.